Compare Humana Inc (HUM) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Philip Morris International Inc. — how do they compare? Humana Inc trades at $378.69 (market cap $46.31B), while Philip Morris International Inc. trades at $186.62 (market cap $289.90B). The key difference: Philip Morris International Inc. is far larger — about 6.3× Humana Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.16%). Which is the better fit depends on your goals.
| HUM | PM | |
|---|---|---|
Market Cap | $46.31B | $289.90B |
Sector | Health | Consumer Staples |
52-Week High | $409.42 | $200.17 |
52-Week Low | $163.67 | $144.33 |
Enterprise Value | $53.67B | $333.02B |
Dividend Yield | 0.92% | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Philip Morris International (PM) trades at $189.57, up 0.81% today, with a bullish technical outlook and strong fundamentals. Recent earnings beats in Q1 and Q2 2026, alongside a 27.91% net margin in 2025, highlight profitability. However, the company faces headwinds from a $500 million impairment charge and reduced 2026 guidance due to cost pressures, as reported by Reuters on June 2, 2026.
The stock offers a dividend yield supported by cash flow, but risks include regulatory challenges and currency volatility. Analysts maintain a buy consensus with a $211.17 target, suggesting 11% upside, though investors should weigh near-term earnings pressure against long-term brand strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
